Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism

Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in comparison to one containing levonorgestrel and ethinylestradiol on markers of endocrine function

(2012) Ulla M. Ågren et al.   EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE

Comparison of a 24-day and a 21-day pill regimen for the novel combined oral contraceptive, nomegestrol acetate and 17 -estradiol (NOMAC/E2): a double-blind, randomized study

(2011) S. Christin-Maitre et al.   HUMAN REPRODUCTION

Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17β-estradiol, compared with those of levonorgestrel/ethinyl estradiol

(2011) Martine Alhenc-Gelas et al.   THROMBOSIS AND HAEMOSTASIS

50 years of "The Pill": celebrating a golden anniversary

(2011) Anne Szarewski et al.   JOURNAL OF FAMILY PLANNING AND REPRODUCTIVE HEALTH CARE

Nomegestrol Acetate

(2010) Stefano Lello   DRUGS

Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol on ovarian function in comparison to a monophasic combined oral contraceptive containing drospirenone and ethinylestradiol

(2010) Ingrid J. M. Duijkers et al.   EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE

Effects of Oral and Transdermal Hormonal Contraception on Vascular Risk Markers

(2010) Julia V. Johnson et al.   OBSTETRICS AND GYNECOLOGY

Oral Contraceptives and Venous Thromboembolism Consensus Opinion from an International Workshop held in Berlin, Germany in December 2009

(2010) Robert L Reid et al.   JOURNAL OF FAMILY PLANNING AND REPRODUCTIVE HEALTH CARE

Risk of venous thromboembolism among users of oral contraceptives: a review of two recently published studies

(2010) Samuel Shapiro et al.   JOURNAL OF FAMILY PLANNING AND REPRODUCTIVE HEALTH CARE

Number Needed to Treat With Rosuvastatin to Prevent First Cardiovascular Events and Death Among Men and Women With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein

(2009) Paul M Ridker et al.